Your browser doesn't support javascript.
loading
Targeting MYC through WDR5.
Thomas, Lance R; Adams, Clare M; Fesik, Stephen W; Eischen, Christine M; Tansey, William P.
Afiliação
  • Thomas LR; Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Adams CM; Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
  • Fesik SW; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Eischen CM; Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
  • Tansey WP; Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Mol Cell Oncol ; 7(2): 1709388, 2020.
Article em En | MEDLINE | ID: mdl-32158922
ABSTRACT
The oncoprotein transcription factor MYC is overexpressed in most cancers and is responsible for hundreds of thousands of cancer deaths worldwide every year. MYC is also a highly validated - but currently undruggable - anti-cancer target. We recently showed that breaking the interaction of MYC with its chromatin co-factor WD repeat-containing protein 5 (WDR5) promotes tumor regression in mouse xenografts, laying the foundation for a new strategy to inhibit MYC in the clinic.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article